Perovial®

Medical device

Perovial® is the first HA-based option for the management of Peyronie’s disease in its acute phase1.

perovial hyaluronic acid injection

Highlights

High level of novelty

Classified as a high level of novelty device1

Improvement

Improvement in penile curvature, plaque size, and erectile function3,4,5,6

Improves outcome

Improves outcome in terms of penile pain reduction and patients’ satisfaction4,5

Good safety and tolerability

Good safety profile and tolerability in clinical studies3,4,5

Protocol

Weekly for 10-12 weeks according to the doctor’s judgment2

Clinical evidence

Regression in plaque size5,6

Perovial® leads to a measurable decrease in penile curvature3,4,5,6

Perovial® improves erectile function4,5

Perovial® showed significant improvement in penile pain compared to verapamil and baseline and patient satisfaction4,5,6

Perovial® showed a good safety profile and good tolerability3,4,5

Contact IBSA
Back to the Perovial® product line

Section reserved for healthcare professionals

This section contains information intended for healthcare professionals. By continuing, you confirm that you are a healthcare professional authorized to access this content.

Are you a healthcare professional (HCP)?

No, go back

References

  • 1 / European Commission. Expert decision and opinion in the context of the Clinical Evaluation Consultation Procedure (CECP).
  • 2 / PEROVIAL®. Instructions for Use.
  • 3 / Favilla V, et al. Andrology. 2017;5(4):771-5.
  • 4 / Cocci A, et al. World J Mens Health. 2021;39(2):352-7.
  • 5 / Zucchi A, et al. Sex Med. 2016;4(2):e83-8.
  • 6 / Cai T, et al. World J Mens Health. 2021;39(3):526-32.